Peginterferon lambda-1a biosimilar (Nanogen Biopharmaceutical)

聚乙二醇化干扰素λ-1a生物类似药 (Nanogen Biopharmaceutical)

Report date: 2024/05/24 20:00:45

Base Information

Drug NamePeginterferon lambda-1a biosimilar (Nanogen Biopharmaceutical)
Drug Alias Name聚乙二醇化干扰素λ-1a生物仿制药 (Nanogen Biopharmaceutical)PeglamdaPegylated interferon lambda 1
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunostimulantsInterferon lambda receptor stimulantsInnate antiviral immune response inducers
TargetsInterferon lambda receptor
Therapy Area/IndicationsHepatitis, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesVietnam
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNanogen Biopharmaceutical Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanogen Pharmaceutical Biotechnology Joint Stock CompanyNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsN/A
Inactive IndicationsHepatitis, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A